245 related articles for article (PubMed ID: 21070501)
1. Treatment related factors and inhibitor development in children with severe haemophilia A.
Maclean PS; Richards M; Williams M; Collins P; Liesner R; Keeling DM; Yee T; Will AM; Young D; Chalmers EA;
Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501
[TBL] [Abstract][Full Text] [Related]
2. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
[TBL] [Abstract][Full Text] [Related]
3. Risk of inhibitor development in mild haemophilia A increases with age.
Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
[TBL] [Abstract][Full Text] [Related]
4. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
Chalmers EA; Brown SA; Keeling D; Liesner R; Richards M; Stirling D; Thomas A; Vidler V; Williams MD; Young D;
Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
[TBL] [Abstract][Full Text] [Related]
5. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.
Kurnik K; Bidlingmaier C; Engl W; Chehadeh H; Reipert B; Auerswald G
Haemophilia; 2010 Mar; 16(2):256-62. PubMed ID: 19878331
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors: our greatest challenge. Can we minimize the incidence?
Kruse-Jarres R
Haemophilia; 2013 Jan; 19 Suppl 1():2-7. PubMed ID: 23278993
[TBL] [Abstract][Full Text] [Related]
7. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
[TBL] [Abstract][Full Text] [Related]
8. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies.
Coppola A; Santoro C; Tagliaferri A; Franchini M; DI Minno G
Haemophilia; 2010 Jan; 16 Suppl 1():13-9. PubMed ID: 20059564
[TBL] [Abstract][Full Text] [Related]
9. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
10. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
Gouw SC; van den Berg HM
Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.
Boekhorst J; Lari GR; D'Oiron R; Costa JM; Nováková IR; Ala FA; Lavergne JM; VAN Heerde WL
Haemophilia; 2008 Jul; 14(4):729-35. PubMed ID: 18503540
[TBL] [Abstract][Full Text] [Related]
12. Haemophilia care in children--benefits of early prophylaxis for inhibitor prevention.
Mancuso ME; Graca L; Auerswald G; Santagostino E
Haemophilia; 2009 Jan; 15 Suppl 1():8-14. PubMed ID: 19125935
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of factor VIII inhibitors.
Hay CR
Haemophilia; 2006 Dec; 12 Suppl 6():23-8; discussion 28-9. PubMed ID: 17123390
[TBL] [Abstract][Full Text] [Related]
14. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
[TBL] [Abstract][Full Text] [Related]
16. Assessing risk factors: prevention of inhibitors in haemophilia.
Chambost H
Haemophilia; 2010 Mar; 16 Suppl 2():10-5. PubMed ID: 20132333
[TBL] [Abstract][Full Text] [Related]
17. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
Unuvar A; Kavakli K; Baytan B; Kazanci E; Sayli T; Oren H; Celkan T; Gursel T
Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor development in hemophiliacs: the roles of genetic versus environmental factors.
Lee CA; Lillicrap D; Astermark J
Semin Thromb Hemost; 2006 Jun; 32 Suppl 2():10-4. PubMed ID: 16804830
[TBL] [Abstract][Full Text] [Related]
20. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A.
Chaves D; Belisário A; Castro G; Santoro M; Rodrigues C
Int J Immunogenet; 2010 Apr; 37(2):79-82. PubMed ID: 20082647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
